Pomalidomide plus rituximab for younger high-risk lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at using two drugs, pomalidomide and rituximab, as maintenance therapy after initial treatment for younger adults with a high-risk type of non-Hodgkin lymphoma called DLBCL. The goal is to see if this combination helps keep the cancer in remission longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 59 years old.
- You have been diagnosed with DLBCL and have had at least a partial response (some shrinkage of the lymphoma) after your first treatment.
- You had a high-risk score on a test called aaIPI at diagnosis, meaning your lymphoma was considered aggressive.
- Your lymphoma was stage II, III, or IV when you were first diagnosed.
- You are generally able to care for yourself (ECOG score 0-2) and have adequate organ function.
- You are not pregnant or breastfeeding and agree to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (CRP regimen) for older patients who have not yet been treated for a specific type of DLBCL called double-expressor lymphoma. It aims to see if this combination is effective and safe for people who may not be able to get standard chemotherapy.
This Phase 1 study tests whether a combination of pomalidomide and a dose-adjusted chemotherapy plan (EPOCH), with or without rituximab, can treat certain aggressive B-cell lymphomas in people living with HIV. It aims to find a safe dosing approach and see how well the treatment works for specific lymphoma types or high risk of spread to the brain.
This study tests a combination of drugs (called R-mini-MCOP) in people 80 years or older with a type of lymphoma called DLBCL that has not been treated before. The goal is to see if this treatment can help control the lymphoma while being safe for older patients.
This trial tests a combination of two drugs, rituximab and CC-99282, as a first treatment for older adults with diffuse large b-cell lymphoma who are too frail for standard chemotherapy. The goal is to see if this gentler approach can effectively control the disease while being easier to tolerate.
This trial tests a combination of three drugs (pomalidomide, rituximab, and methotrexate) for people who have just been diagnosed with a type of lymphoma that started in the brain or spinal cord. The goal is to see if this drug cocktail is safe and effective as a first treatment.
This trial tests a combination of four medications (pomalidomide, rituximab, orelabrutinib, and polatuzumab vedotin) for newly diagnosed, elderly patients with diffuse large B-cell lymphoma (DLBCL) who cannot tolerate standard treatments. It aims to see if this combination is effective and safe for older adults.
Hear when a new Diffuse Large B-Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.